NCT06801665

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date: Sep 15, 2025
Primary completion: Feb 1, 2027
Completion date: Feb 1, 2027
First posted: Jan 30, 2025
Last posted: Sep 3, 2025
Enrollment: 30
Arms / groups: 1 / —
Source: AACT · ctgov ingestion

Drugs studied

bevacizumab
capecitabine
human fecal microbiota
oxaliplatin
ql1706

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.

NCT06801665

Timeline

Sponsors

Drugs studied